Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Indian Journal of Novel Drug Delivery
J Public Health (Berl.) 2022;30:2819-28
Q
If the focus is purely on weight-loss potential rather than market familiarity, retatrutide has the stronger science-driven case
Key Observations from Phase 2 Data Dose escalation reduced adverse events: Groups that used gradual dose titration reported fewer GI events than those starting at the target dose directly No deaths were attributed to the study drug Serious adverse events were reported at low rates across all groups, with no clear dose-dependent pattern for serious events The placebo group also reported substantial adverse events (72.1%), which is typical for trials of this size and duration TRIUMPH Phase 3 Adverse Event Profiles The TRIUMPH program consists of eight Phase 3 trials evaluating retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD)
Blissenbach Board Certified Excellence Dr
US$ 24.92
US$ 25.50
US$ 27.56
US$ 26.59
US$ 27.08
US$ 20.09
